Fourth Annual Multidisciplinary Interactive Thoracic Oncology Conference

The CBCE
Last Modified: November 21, 2007

Share article


Conference Dates: April 11-12, 2008
Conference Location: Seattle, WA

Sponsoring Group: The CBCE

Conference Web Page URL: http://www.thecbce.com

Conference Objectives: After attending this activity, participants should be able to:

  1. Describe the standard of care for patients with early-stage NSCLC, and discuss recent trials incorporating adjuvant and/or neoadjuvant chemotherapy into treatment regimens for patients eligible for surgery.
  2. Evaluate current clinical trial data addressing the safety and efficacy of various chemoradiotherapeutic regimens in the treatment of patients with locally advanced NSCLC.
  3. Compare treatment options for elderly patients with NSCLC, taking into consideration patient comorbidities, performance status, and adverse responses to systemic therapy.
  4. Assess the results from recent studies aimed at identifying markers and patient characteristics that are predictive of response to specific EGFR inhibitors.
  5. Summarize alternative or additional treatment approaches, such as maintenance therapy and PCI, which may potentially lead to improved clinical outcomes for patients with NSCLC.
  6. Evaluate the results of recent studies investigating therapy options for the treatment of SCLC.

Who Should Attend: This activity is designed for lung cancer specialists, medical oncologists, radiation oncologists, surgical oncologists, thoracic surgeons, nurses, pharmacists, advanced practitioners, and other health care professionals involved in the treatment of patients with thoracic malignancies.

Registration Information: To learn more about the Fourth Annual Multidisciplinary Thoracic Oncology Conference and to register, please visit http://www.thecbce.com, e-mail info@thecbce.com, or call (214) 260-9024.

Continuing Education: Yes


News
Genetic markers indicate which non-small-cell lung cancer patients may benefit from adjuvant therapy

Dec 16, 2010 - Using a tool based on six gene markers, oncologists may be better able to identify stage I non-small-cell lung cancer patients more at risk for relapse who might benefit from adjuvant therapy, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, held from Dec. 9 to 11.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More